Award will support innovative research to develop methodologies, establish feasibility, or pilot high risk/high reward projects.
Yosemite, an oncology-focused venture capital firm based in San Francisco, CA, and ACS have announced the launch of the Yosemite-American Cancer Society Award (Yosemite-ACS Award) with an initial commitment of $13.2 million. The grant program will support innovative research to develop methodologies, establish feasibility, or pilot high risk/high reward projects to advance the pr
evention, diagnosis, or treatment of cancer.
Yosemite and ACS developed the highly competitive Yosemite-ACS Award to make an immediate impact in supporting innovative research taking place at prominent institutions across the country.
“Funding innovative research is a critical tool in our efforts to improve the lives of cancer patients and their families. In joining forces, ACS and Yosemite will work to advance the most promising research through the Yosemite-ACS Award,” said Dr. Karen E. Knudsen, CEO for the American Cancer Society. “The American Cancer Society is honored to partner with Yosemite and to provide this bold platform to advance cancer discoveries that will save lives.”
The Yosemite-ACS Award aims to support a range of dedicated investigators from early career to nationally recognized scientists focused on the most promising science to advance key areas of cancer research. The two-year Yosemite-ACS Award offers up to $330,000 for one or two-year projects related to (1) the application of transformative AI models to make novel discoveries impacting cancer patients, and (2) research in immuno-oncology and cell therapy approaches.
The Yosemite-ACS Award will include a rigorous peer review process evaluating approach, innovation, and impact. Selection of the grantees will be made jointly by Yosemite and ACS following recommendation and review with the Yosemite-ACS Award Scientific Advisory Board (SAB).
Like and share on X (formerly Twitter.)
